Abstract: OBJECTIVE To compare the cost-effectiveness of using dry powder inhalers(DPIs) whether testing ADRB2 Genetic Polymorphisms in Chinese COPD patients, and to provide economical references for reasonable clinical prescription based Pharmacogenomics. METHODS From a society-wide perspective, a decision tree model was developed to calculate medical cost and health outcomes of using DPIs in Chinese COPD patients based testing ADRB2 genetic polymorphisms, cost-effectiveness analysis and sensitivity analysis were used to evaluate its economy. RESULTS The results of cost-effectiveness analysis showed that the expected cost of regimen of using DPIs by ADRB2 testing(AT) was 12 170.78 Yuan, the expected Quality-adjusted life years(QALY) was 0.411 8, and the cost effectiveness ratio(CER) was 29 555.08 Yuan/QALY. And the expected cost of regimen of using DPIs by no testing(NT) was 11 711.01 Yuan, the expected QALY was 0.407 8, CER of NT was 28 717.53 Yuan/QALY. The incremental cost-effectiveness ratio (ICER) of AT and NT regimen was 114 942.96, Less than the willingness to pay(WTP) set (3 times China's per capita GDP in 2017:177 785.28 Yuan) in this study, it illustrated that AT regimen was economical. Results of single factor sensitivity analysis demonstrated that price of ADRB2 testing and ADRB2 genetic polymorphism had a greater impact on ICER results, probabilistic sensitivity analysis showed that AT regimen had more economical than NT regimen, but the superiority was relatively insignificant. CONCLUSION Within the level of WTP, AT regimen was an economically acceptable solution, however, sensitivity analysis result can not yet determine which regimen was the best one.